Table 2. In vitro activities of PAAG in combination with oxacillin against clinical isolates of multidrug-resistant S. aureus.
| S. aureus Strains | MIC (μg/mL) | FIC* PAAG/OXA | Relationship | |
|---|---|---|---|---|
| PAAG [with OXA] | OXA [with PAAG)] | |||
| MW-2 | 2 | 1 | 0.2 | Synergistic |
| SA01 | 2 | 2 | 0.2 | Synergistic |
| SA02 | 4 | 8 | 0.4 | Synergistic |
| SA03 | 4 | 4 | 0.5 | Synergistic |
| SA04 | 4 | 2 | 0.4 | Synergistic |
| SA05 | 4 | 1 | 0.4 | Synergistic |
| SA06 | 4 | 1 | 0.4 | Synergistic |
| SA07 | 4 | 1 | 0.3 | Synergistic |
| SA08 | 4 | 2 | 0.1 | Synergistic |
| SA09 | 8 | 4 | 0.5 | Synergistic |
| SA10 | 16 | 1 | 0.5 | Synergistic |
| SA11 | 2 | 4 | 0.3 | Synergistic |
| SA12 | 2 | 1 | 0.1 | Synergistic |
| 2-1A | 4 | 2 | 0.2 | Synergistic |
| 2-4C | 8 | 1 | 0.2 | Synergistic |
| 2-5A | 4 | 1 | 0.3 | Synergistic |
| 2-9A | 16 | 1 | 0.3 | Synergistic |
*FICA/B = FICA + FICB, where FICA = MIC of A (combination)/ (MIC of A alone) and FICB = MIC of B(combination)/ (MIC of B alone). The FICI interpretation used was FICI < 0.5 synergy, 0.5 < FICI < 4 additive effects or indifference, and FICI ≥ 4 antagonism.